Recro Pharma (REPH) Short Interest Ratio & Short Volume

Short interest is the volume of Recro Pharma shares that have been sold short but have not yet been closed out or covered. As of February 28th, traders have sold 669,900 shares of REPH short. 1.58% of Recro Pharma's shares are currently sold short. Learn More on Recro Pharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. REPH shares currently have a short interest ratio of 4.0. Learn More on Recro Pharma's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.58% of Recro Pharma's floating shares are currently sold short.

Recro Pharma saw a decline in short interest in February. As of February 28th, there was short interest totaling 669,900 shares, a decline of 9.9% from the previous total of 743,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Recro Pharma currently has issued a total of 56,424,000 shares. Some of Recro Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Recro Pharma currently has a public float of 42,320,000 shares.

1.58% of Recro Pharma's shares are currently sold short. Here is how the short interest of companies compare to Recro Pharma: Capricor Therapeutics Inc (26.67%), Verve Therapeutics, Inc. (25.05%), Eton Pharmaceuticals, Inc. (1.82%), ABIVAX Société Anonyme (2.83%), Sage Therapeutics, Inc. (8.06%), Precigen, Inc. (15.62%), Erasca, Inc. (14.36%), Zevra Therapeutics, Inc. (10.94%), Prothena Co. plc (18.64%), PureTech Health plc (0.05%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($5.96 billion), Palo Alto Networks, Inc. ($4.37 billion), Lucid Group, Inc. ($2.87 billion), Moderna, Inc. ($2.70 billion), Rivian Automotive, Inc. ($2.31 billion), Wayfair Inc. ($2.29 billion), Snap Inc. ($2.23 billion), Datadog, Inc. ($2.21 billion), Live Nation Entertainment, Inc. ($1.96 billion), and Zoom Video Communications, Inc. ($1.89 billion). View all of the most shorted stocks.

Short selling REPH is an investing strategy that aims to generate trading profit from Recro Pharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Recro Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of REPH, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including REPH, twice per month. The most recent reporting period available is February, 28 2022.